Bayer says FDA grants priority review designation for finerenone
- Posted on May 22, 2026
- By Bing News
- 0 Views
- 1 min read
Bayer says FDA grants priority review designation for finerenone
(Corrects May 21 story to clarify finerenone is currently used to treat type 2, not type 1 diabetes, in second paragraph) May 21 (Reuters) - Bayer said on Thursday that the U.S. Food and Drug Administration had accepted its supplemental New Drug Application for finerenone and granted priority review designation. Finerenone, marketed as Kerendia, is used for the treatment of chronic kidney
